Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Page Path

HOME
ARTICLE CATEGORY
Review

Review

Preventive strategy for nonalcoholic fatty liver disease-related hepatocellular carcinoma

Yuri Cho, Bo Hyun Kim, Joong-Won Park

Clin Mol Hepatol. 2023;29(Suppl):S220-S227. Published online November 10, 2022

DOI: https://doi.org/10.3350/cmh.2022.0360

View: 4006 Download: 137 Web of Science: 5 Crossref: 5

Non-alcoholic fatty liver disease: the pathologist’s perspective

Wei-Qiang Leow, Anthony Wing-Hung Chan, Paulo Giovanni L. Mendoza, Regina Lo, Kihan Yap, Haeryoung Kim

Clin Mol Hepatol. 2023;29(Suppl):S302-S318. Published online November 15, 2022

DOI: https://doi.org/10.3350/cmh.2022.0329

View: 5966 Download: 294 Web of Science: 11 Crossref: 12

Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future

Tina Reinson, Ryan M. Buchanan, Christopher D. Byrne

Clin Mol Hepatol. 2023;29(Suppl):S157-S170. Published online November 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0348

View: 4676 Download: 318 Web of Science: 17 Crossref: 17

Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease

Peter Konyn, Aijaz Ahmed, Donghee Kim

Clin Mol Hepatol. 2023;29(Suppl):S43-S57. Published online November 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0351

View: 4691 Download: 179 Web of Science: 30 Crossref: 31

MAFLD: How is it different from NAFLD?

Cameron Gofton, Yadhavan Upendran, Ming-Hua Zheng, Jacob George

Clin Mol Hepatol. 2023;29(Suppl):S17-S31. Published online November 29, 2022

DOI: https://doi.org/10.3350/cmh.2022.0367

View: 16710 Download: 1,227 Web of Science: 101 Crossref: 119

Screening strategy for non-alcoholic fatty liver disease

Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto

Clin Mol Hepatol. 2023;29(Suppl):S103-S122. Published online November 30, 2022

DOI: https://doi.org/10.3350/cmh.2022.0336

View: 5438 Download: 251 Web of Science: 14 Crossref: 16

Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response

Silvia Sookoian, Carlos J. Pirola

Clin Mol Hepatol. 2023;29(Suppl):S184-S195. Published online December 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0318

View: 4410 Download: 190 Web of Science: 11 Crossref: 13

Comparison between obese and non-obese nonalcoholic fatty liver disease

Wah-Kheong Chan

Clin Mol Hepatol. 2023;29(Suppl):S58-S67. Published online December 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0350

View: 6068 Download: 283 Web of Science: 17 Crossref: 23

Interaction between sarcopenia and nonalcoholic fatty liver disease

Sae Kyung Joo, Won Kim

Clin Mol Hepatol. 2023;29(Suppl):S68-S78. Published online December 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0358

View: 5659 Download: 316 Web of Science: 27 Crossref: 28

Identification of high-risk subjects in nonalcoholic fatty liver disease

Christiane Stern, Laurent Castera

Clin Mol Hepatol. 2023;29(Suppl):S196-S206. Published online December 5, 2022

DOI: https://doi.org/10.3350/cmh.2022.0431

View: 6095 Download: 285 Web of Science: 9 Crossref: 10

Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future

Asako Nogami, Masato Yoneda, Michihiro Iwaki, Takashi Kobayashi, Yasushi Honda, Yuji Ogawa, Kento Imajo, Satoru Saito, Atsushi Nakajima

Clin Mol Hepatol. 2023;29(Suppl):S123-S135. Published online December 12, 2022

DOI: https://doi.org/10.3350/cmh.2022.0357

View: 4520 Download: 211 Web of Science: 12 Crossref: 12

Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future

Jung Hwan Yu, Han Ah Lee, Seung Up Kim

Clin Mol Hepatol. 2023;29(Suppl):S136-S149. Published online December 12, 2022

DOI: https://doi.org/10.3350/cmh.2022.0436

View: 4587 Download: 228 Web of Science: 20 Crossref: 19

Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future

Terry Cheuk-Fung Yip, Fei Lyu, Huapeng Lin, Guanlin Li, Pong-Chi Yuen, Vincent Wai-Sun Wong, Grace Lai-Hung Wong

Clin Mol Hepatol. 2023;29(Suppl):S171-S183. Published online December 12, 2022

DOI: https://doi.org/10.3350/cmh.2022.0426

View: 5226 Download: 283 Web of Science: 13 Crossref: 13

Risk factors in nonalcoholic fatty liver disease

Eunji Ko, Eileen L. Yoon, Dae Won Jun

Clin Mol Hepatol. 2023;29(Suppl):S79-S85. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0398

View: 5050 Download: 242 Web of Science: 25 Crossref: 26

Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis

Yi-wen Shi, Jian-Gao Fan

Clin Mol Hepatol. 2023;29(Suppl):S228-S243. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0401

View: 4078 Download: 112

Global incidence and prevalence of nonalcoholic fatty liver disease

Margaret LP Teng, Cheng Han Ng, Daniel Q. Huang, Kai En Chan, Darren JH Tan, Wen Hui Lim, Ju Dong Yang, Eunice Tan, Mark D. Muthiah

Clin Mol Hepatol. 2023;29(Suppl):S32-S42. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0365

View: 12940 Download: 506 Web of Science: 137 Crossref: 155

Eating, diet, and nutrition for the treatment of non-alcoholic fatty liver disease

Georg Semmler, Christian Datz, Michael Trauner

Clin Mol Hepatol. 2023;29(Suppl):S244-S260. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0364

View: 6579 Download: 333 Web of Science: 8 Crossref: 9

Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials

Jihyun An, Joo Hyun Sohn

Clin Mol Hepatol. 2023;29(Suppl):S268-S275. Published online December 20, 2022

DOI: https://doi.org/10.3350/cmh.2022.0437

View: 3718 Download: 210 Web of Science: 10 Crossref: 14

Bariatric surgery for non-alcoholic fatty liver disease: Indications and post-operative management

Anja Geerts, Sander Lefere

Clin Mol Hepatol. 2023;29(Suppl):S276-S285. Published online December 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0373

View: 4121 Download: 144 Web of Science: 7 Crossref: 8

The effects of moderate alcohol consumption on non-alcoholic fatty liver disease

Hyunwoo Oh, Won Sohn, Yong Kyun Cho

Clin Mol Hepatol. 2023;29(Suppl):S261-S267. Published online December 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0393

View: 3669 Download: 123 Web of Science: 6 Crossref: 6

Non-alcoholic fatty liver disease: Definition and subtypes

Seul Ki Han, Soon Koo Baik, Moon Young Kim

Clin Mol Hepatol. 2023;29(suppl):S5-S16. Published online December 28, 2022

DOI: https://doi.org/10.3350/cmh.2022.0424

View: 8043 Download: 532 Web of Science: 55 Crossref: 58

Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management

Sara Battistella, Francesca D’Arcangelo, Marco Grasso, Alberto Zanetto, Martina Gambato, Giacomo Germani, Marco Senzolo, Francesco Paolo Russo, Patrizia Burra

Clin Mol Hepatol. 2023;29(Suppl):S286-S301. Published online December 28, 2022

DOI: https://doi.org/10.3350/cmh.2022.0392

View: 6365 Download: 265 Web of Science: 16 Crossref: 16

Nonalcoholic fatty liver disease and non-liver comorbidities

Richie Manikat, Mindie H. Nguyen

Clin Mol Hepatol. 2023;29(Suppl):s86-s102. Published online January 5, 2023

DOI: https://doi.org/10.3350/cmh.2022.0442

View: 5795 Download: 219 Web of Science: 10 Crossref: 13

Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments

Sang Bong Ahn

Clin Mol Hepatol. 2023;29(Suppl):S150-S156. Published online January 25, 2023

DOI: https://doi.org/10.3350/cmh.2022.0362

View: 4303 Download: 231 Web of Science: 9 Crossref: 8

Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Kuei-Chuan Lee, Pei-Shan Wu, Han-Chieh Lin

Clin Mol Hepatol. 2023;29(1):77-98. Published online October 13, 2022

DOI: https://doi.org/10.3350/cmh.2022.0237

View: 10984 Download: 706 Web of Science: 57 Crossref: 56

Hepatocytes infected with hepatitis C virus change immunological features in the liver microenvironment

Soo-Jeung Park, Young S. Hahn

Clin Mol Hepatol. 2023;29(1):65-76. Published online August 12, 2022

DOI: https://doi.org/10.3350/cmh.2022.0032

View: 5852 Download: 184 Web of Science: 12 Crossref: 13

Development and prognosis of hepatocellular carcinoma in patients with diabetes

Takuma Nakatsuka, Ryosuke Tateishi

Clin Mol Hepatol. 2023;29(1):51-64. Published online July 29, 2022

DOI: https://doi.org/10.3350/cmh.2022.0095

View: 5782 Download: 245 Web of Science: 20 Crossref: 19

Wnt signaling in liver regeneration, disease, and cancer

Gengyi Zou, Jae-Il Park

Clin Mol Hepatol. 2023;29(1):33-50. Published online July 4, 2022

DOI: https://doi.org/10.3350/cmh.2022.0058

View: 6903 Download: 275 Web of Science: 16 Crossref: 18

Management of refractory ascites

Florence Wong

Clin Mol Hepatol. 2023;29(1):16-32. Published online June 9, 2022

DOI: https://doi.org/10.3350/cmh.2022.0104

View: 11017 Download: 932 Web of Science: 17 Crossref: 17

Subclinical versus advanced forms of alcohol-related liver disease: Need for early detection

Concepción Gómez-Medina, Luma Melo, David Martí-Aguado, Ramón Bataller

Clin Mol Hepatol. 2023;29(1):1-15. Published online April 15, 2022

DOI: https://doi.org/10.3350/cmh.2022.0017

View: 9908 Download: 190 Web of Science: 5 Crossref: 6

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

Impact Factor

14.0
First decision

07 Days

Publication after acceptance

03 Days

*Last 12 months

Viewed By 5165	MAFLD: How is it different from NAFLD?
Viewed By 4913	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4878	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 4608	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 4584	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 219	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 155	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 134	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 119	MAFLD: How is it different from NAFLD?
Cited By 96	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach